ID   C106 [Human rectal adenocarcinoma]
AC   CVCL_M011
DR   cancercelllines; CVCL_M011
DR   CancerTools; 151762
DR   ColonAtlas; C106
DR   Cosmic; 948836
DR   Cosmic; 986002
DR   Cosmic; 995375
DR   Cosmic; 1312289
DR   Cosmic; 2301956
DR   Cosmic; 2800588
DR   ECACC; 12022906
DR   GEO; GSM1346861
DR   GEO; GSM1374419
DR   GEO; GSM1448197
DR   IARC_TP53; 21733
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   Wikidata; Q54807830
DR   Ximbio; 151762
RX   PubMed=10051639;
RX   PubMed=10737795;
RX   PubMed=16418264;
RX   PubMed=18258742;
RX   PubMed=20606684;
RX   PubMed=24755471;
RX   PubMed=25926053;
RX   PubMed=29101300;
CC   Microsatellite instability: Stable (MSS) (PubMed=24755471; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Gln1237Glufs*2 (c.3709_3710delCA); ClinVar=VCV000433651; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.His1490fs*17 (c.4469delA); Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Thr125Met (c.374C>T); ClinVar=VCV000183748; Zygosity=Unspecified (PubMed=16418264).
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: ECACC; 12022906; true.
CC   Derived from site: In situ; Rectum; UBERON=UBERON_0001052.
ST   Source(s): ECACC=12022906; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,14
ST   D16S539: 12,13
ST   D21S11: 32.2
ST   D5S818: 12
ST   D7S820: 8,10
ST   TH01: 6
ST   TPOX: 10,11
ST   vWA: 18
DI   NCIt; C9383; Rectal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   78Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 19-12-24; Version: 28
//
RX   PubMed=10051639; DOI=10.1073/pnas.96.5.2316; PMCID=PMC26781;
RA   Efstathiou J.A., Liu D., Wheeler J.M.D., Kim H.C., Beck N.E., Ilyas M.,
RA   Karayiannakis A.J., Mortensen N.J., Kmiot W.A.W., Playford R.J.,
RA   Pignatelli M., Bodmer W.F.;
RT   "Mutated epithelial cadherin is associated with increased
RT   tumorigenicity and loss of adhesion and of responsiveness to the
RT   motogenic trefoil factor 2 in colon carcinoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2316-2321(1999).
//
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352; PMCID=PMC16243;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J.M.D., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103; PMCID=PMC1327731;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of p53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105; PMCID=PMC2268141;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780; PMCID=PMC2920028;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701; PMCID=PMC5731344;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D.J., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//